Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

What do women with gynecologic cancer know about HPV and their individual disease? A pilot study

Authors: Sophie Pils, Elmar A Joura, Max-Paul Winter, Anup Shrestha, Agnes Jaeger-Lansky, Johannes Ott

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The vaccinations against human papilloma virus (HPV) are highly effective in preventing persistent infection. The level of knowledge about HPV and the consequences of an infection with this virus are low in the general population and in patients who suffer from HPV-associated diseases. We aimed to compare the level of knowledge about HPV and about the women’s individual malignant disease between women with and without HPV-associated gynecologic cancer as well as the knowledge about individual malignant diseases.

Methods

In a pilot study, 51 women with HPV-related cancer (cervical cancer: n = 30; vulvar or vaginal cancer: n = 21) and 60 women with non-HPV associated gynecologic malignancies (ovarian cancer: n = 30; endometrial cancer, n = 30) were included. They answered a questionnaire including questions about personal medical history, risk factors for cancer development, and HPV.

Results

The general level of knowledge of the term “HPV” was low (29.7%, 33/111) and it was similar in patients with HPV-related and non-HPV-associated cancer (18/60, 30.0% vs. 15/51, 29.4%, respectively; p = 1.000). When asked about their disease, 80% (24/30) of women with ovarian cancer correctly named their diagnosis, followed by women with cervical cancer (73.3%, 22/30), endometrial cancer (70%, 21/30) and vaginal or vulvar cancer (42.9%, 9/21; p = 0.008).

Conclusion

The level of knowledge about HPV and the malignant diseases the patient suffered from was low. This applied even to patients with HPV associated malignancies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166. doi:10.3322/caac.21166CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166. doi:10.3322/caac.21166CrossRefPubMed
2.
go back to reference Breslow RA, Sorkin JD, Frey CM, Kessler LG: Americans’ knowledge of cancer risk and survival. Prev Med. 1997, 26 (2): 170-177. 10.1006/pmed.1996.0136.CrossRefPubMed Breslow RA, Sorkin JD, Frey CM, Kessler LG: Americans’ knowledge of cancer risk and survival. Prev Med. 1997, 26 (2): 170-177. 10.1006/pmed.1996.0136.CrossRefPubMed
3.
go back to reference Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D: Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet. 2011, 284: 169-174. 10.1007/s00404-011-1850-9.CrossRefPubMed Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D: Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet. 2011, 284: 169-174. 10.1007/s00404-011-1850-9.CrossRefPubMed
4.
go back to reference Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer. Virol J. 2011, 8: 269-10.1186/1743-422X-8-269.CrossRefPubMedPubMedCentral Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer. Virol J. 2011, 8: 269-10.1186/1743-422X-8-269.CrossRefPubMedPubMedCentral
5.
go back to reference Lacey JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A: Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003, 98: 814-821. 10.1002/cncr.11567.CrossRefPubMed Lacey JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A: Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003, 98: 814-821. 10.1002/cncr.11567.CrossRefPubMed
6.
go back to reference Ramus SJ, Gayther SA: The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009, 3: 138-150. 10.1016/j.molonc.2009.02.001.CrossRefPubMed Ramus SJ, Gayther SA: The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009, 3: 138-150. 10.1016/j.molonc.2009.02.001.CrossRefPubMed
7.
go back to reference Edgren G, Sparen P: Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007, 8: 311-316. 10.1016/S1470-2045(07)70043-8.CrossRefPubMed Edgren G, Sparen P: Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007, 8: 311-316. 10.1016/S1470-2045(07)70043-8.CrossRefPubMed
8.
go back to reference Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, FUTURE I and II Study Group: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012, 344: e1401-10.1136/bmj.e1401.CrossRefPubMedPubMedCentral Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, FUTURE I and II Study Group: Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012, 344: e1401-10.1136/bmj.e1401.CrossRefPubMedPubMedCentral
9.
go back to reference Sathish N, Wang X, Yuan Y: Human papillomavirus (HPV)-associated oral cancers and treatment strategies. J Dent Res. 2014, doi:10.1177/0022034514527969 Sathish N, Wang X, Yuan Y: Human papillomavirus (HPV)-associated oral cancers and treatment strategies. J Dent Res. 2014, doi:10.1177/0022034514527969
10.
go back to reference Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002, 347: 1645-1651. 10.1056/NEJMoa020586.CrossRefPubMed Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002, 347: 1645-1651. 10.1056/NEJMoa020586.CrossRefPubMed
11.
go back to reference Donders GG, Gabrovska M, Bellen G, Van Keirsbilck J, Van Den Bosch T, Riphagen I, Verjans M: Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Arch Gynecol Obstet. 2008, 277: 291-298. 10.1007/s00404-007-0487-1.CrossRefPubMed Donders GG, Gabrovska M, Bellen G, Van Keirsbilck J, Van Den Bosch T, Riphagen I, Verjans M: Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Arch Gynecol Obstet. 2008, 277: 291-298. 10.1007/s00404-007-0487-1.CrossRefPubMed
12.
go back to reference Dahlstrom LA, Sundstrom K, Young C, Lundholm C, Sparen P, Tran TN: Awareness and knowledge of human papillomavirus in the Swedish adult population. J Adolesc Health. 2012, 50: 204-206. 10.1016/j.jadohealth.2011.05.009.CrossRefPubMed Dahlstrom LA, Sundstrom K, Young C, Lundholm C, Sparen P, Tran TN: Awareness and knowledge of human papillomavirus in the Swedish adult population. J Adolesc Health. 2012, 50: 204-206. 10.1016/j.jadohealth.2011.05.009.CrossRefPubMed
13.
go back to reference Muhlhauser I, Lenz M: Does patient knowledge improve treatment outcome?. Z Evid Fortbild Qual Gesundhwes. 2008, 102: 223-230. 10.1016/j.zefq.2008.04.002.CrossRefPubMed Muhlhauser I, Lenz M: Does patient knowledge improve treatment outcome?. Z Evid Fortbild Qual Gesundhwes. 2008, 102: 223-230. 10.1016/j.zefq.2008.04.002.CrossRefPubMed
14.
go back to reference Tan EK, Hameed S, Fook-Chong S, Hussein K, Lum SY, Chan LL: Treatment outcome correlates with knowledge of disease in hemifacial spasm. Clin Neurol Neurosurg. 2008, 110: 813-817. 10.1016/j.clineuro.2008.05.010.CrossRefPubMed Tan EK, Hameed S, Fook-Chong S, Hussein K, Lum SY, Chan LL: Treatment outcome correlates with knowledge of disease in hemifacial spasm. Clin Neurol Neurosurg. 2008, 110: 813-817. 10.1016/j.clineuro.2008.05.010.CrossRefPubMed
15.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed
16.
go back to reference Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356: 1928-1943. 10.1056/NEJMoa061760.CrossRefPubMed Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356: 1928-1943. 10.1056/NEJMoa061760.CrossRefPubMed
17.
go back to reference Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs. 2010, 70: 1079-1098. 10.2165/10898580-000000000-00000.CrossRefPubMed Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs. 2010, 70: 1079-1098. 10.2165/10898580-000000000-00000.CrossRefPubMed
18.
go back to reference Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr C, Paavonen J: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007, 369: 1693-1702. 10.1016/S0140-6736(07)60777-6.CrossRefPubMed Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr C, Paavonen J: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007, 369: 1693-1702. 10.1016/S0140-6736(07)60777-6.CrossRefPubMed
19.
go back to reference Schmeink CE, Gosens KC, Melchers WJ, Massuger LF, Bekkers RL: Young adults awareness of HPV and vaccine acceptance after introduction of the HPV vaccine in the Dutch national vaccination program. Eur J Gynaecol Oncol. 2011, 32: 481-486.PubMed Schmeink CE, Gosens KC, Melchers WJ, Massuger LF, Bekkers RL: Young adults awareness of HPV and vaccine acceptance after introduction of the HPV vaccine in the Dutch national vaccination program. Eur J Gynaecol Oncol. 2011, 32: 481-486.PubMed
20.
go back to reference Trim K, Nagji N, Elit L, Roy K: Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstet Gynecol Int. 2012, 2012: 921236-CrossRefPubMed Trim K, Nagji N, Elit L, Roy K: Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstet Gynecol Int. 2012, 2012: 921236-CrossRefPubMed
21.
go back to reference Almeida CM, Tiro JA, Rodriguez MA, Diamant AL: Evaluating associations between sources of information, knowledge of the human papillomavirus, and human papillomavirus vaccine uptake for adult women in California. Vaccine. 2012, 30: 3003-3008. 10.1016/j.vaccine.2012.01.079.CrossRefPubMed Almeida CM, Tiro JA, Rodriguez MA, Diamant AL: Evaluating associations between sources of information, knowledge of the human papillomavirus, and human papillomavirus vaccine uptake for adult women in California. Vaccine. 2012, 30: 3003-3008. 10.1016/j.vaccine.2012.01.079.CrossRefPubMed
22.
go back to reference Waller J, Ostini R, Marlow LA, McCaffery K, Zimet G: Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. Prev Med. 2013, 56: 35-40. 10.1016/j.ypmed.2012.10.028.CrossRefPubMed Waller J, Ostini R, Marlow LA, McCaffery K, Zimet G: Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. Prev Med. 2013, 56: 35-40. 10.1016/j.ypmed.2012.10.028.CrossRefPubMed
23.
go back to reference Insinga RP, Glass AG, Rush BB: The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004, 191: 114-120. 10.1016/j.ajog.2004.01.042.CrossRefPubMed Insinga RP, Glass AG, Rush BB: The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004, 191: 114-120. 10.1016/j.ajog.2004.01.042.CrossRefPubMed
24.
go back to reference Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374: 301-314. 10.1016/S0140-6736(09)61248-4.CrossRefPubMed Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374: 301-314. 10.1016/S0140-6736(09)61248-4.CrossRefPubMed
25.
go back to reference Laz TH, Rahman M, Berenson AB: An update on human papillomavirus vaccine uptake among 11–17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine. 2012, 30: 3534-3540. 10.1016/j.vaccine.2012.03.067.CrossRefPubMedPubMedCentral Laz TH, Rahman M, Berenson AB: An update on human papillomavirus vaccine uptake among 11–17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine. 2012, 30: 3534-3540. 10.1016/j.vaccine.2012.03.067.CrossRefPubMedPubMedCentral
26.
go back to reference Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL: Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012, 30: 3546-3556. 10.1016/j.vaccine.2012.03.063.CrossRefPubMed Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL: Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012, 30: 3546-3556. 10.1016/j.vaccine.2012.03.063.CrossRefPubMed
Metadata
Title
What do women with gynecologic cancer know about HPV and their individual disease? A pilot study
Authors
Sophie Pils
Elmar A Joura
Max-Paul Winter
Anup Shrestha
Agnes Jaeger-Lansky
Johannes Ott
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-388

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine